| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/100 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | JAM2; JAMB; JAM-B; VEJAM; PRO245; VE-JAM; C21orf43 |
| Entrez GeneID | 58494 |
| clone | 7E4C5 |
| WB Predicted band size | 33.2kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD322 (AA: extra 29-238) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CD322(JAM-C)抗体的参考文献示例(内容为虚构模拟，仅供参考格式)：
1. **文献名称**: *CD322/JAM-C regulates endothelial cell permeability and leukocyte transmigration in inflammatory responses*
**作者**: Ebnet K, et al.
**摘要**: 研究揭示了CD322/JAM-C在炎症反应中通过调控内皮细胞间连接的通透性，促进中性粒细胞和T细胞的跨内皮迁移，为靶向CD322抗体治疗炎症性疾病提供理论基础。
2. **文献名称**: *Targeting CD322/JAM-C with monoclonal antibodies inhibits tumor angiogenesis and metastasis*
**作者**: Lamagna C, et al.
**摘要**: 通过开发靶向CD322的单克隆抗体，实验证明其可阻断肿瘤血管生成并抑制黑色素瘤模型中的转移，表明CD322抗体在抗肿瘤治疗中的潜力。
3. **文献名称**: *Structural characterization of CD322/JAM-C and its interaction with integrin LFA-1*
**作者**: Arrate MP, et al.
**摘要**: 利用X射线晶体学解析CD322的胞外结构域，阐明其与整合素LFA-1的结合机制，为设计阻断免疫细胞黏附的CD322抗体提供结构依据。
4. **文献名称**: *CD322 antibody modulates autoimmune responses by altering T cell polarization*
**作者**: Johnson Z, et al.
**摘要**: 研究发现抗CD322抗体可通过干扰T细胞与抗原呈递细胞的相互作用，调节Th1/Th2平衡，减轻实验性自身免疫性脑脊髓炎症状。
(注：以上文献及作者为示例性虚构，实际研究需通过PubMed等数据库检索确认。)
CD322. also known as Junctional Adhesion Molecule-C (JAM-C), is a transmembrane glycoprotein belonging to the immunoglobulin superfamily. It features two extracellular V-type immunoglobulin (Ig) domains and mediates cell-cell adhesion through homophilic or heterophilic interactions. Primarily expressed on endothelial cells, epithelial cells, platelets, and immune cells, JAM-C plays critical roles in maintaining vascular permeability, leukocyte transmigration, and barrier integrity. It regulates inflammatory responses by facilitating leukocyte recruitment to sites of injury or infection and modulates angiogenesis through interactions with integrins or other adhesion receptors.
CD322 antibodies are tools for studying JAM-C's biological functions and therapeutic potential. In research, these antibodies block JAM-C activity to investigate its involvement in inflammatory diseases (e.g., rheumatoid arthritis, atherosclerosis), cancer progression (e.g., tumor angiogenesis, metastasis), and thrombotic disorders. Preclinical studies suggest that inhibiting JAM-C with antibodies may reduce pathological leukocyte infiltration or disrupt tumor vasculature. However, its dual roles in pro-inflammatory and barrier-protective pathways require context-specific therapeutic strategies. CD322 antibodies are also used in flow cytometry and immunohistochemistry to analyze JAM-C expression patterns in health and disease. Ongoing research aims to refine antibody specificity and evaluate clinical applications, particularly in targeting JAM-C-associated pathological processes.
×
